Medical Oncology

, 33:47 | Cite as

Peptide receptor radionuclide therapy for metastatic paragangliomas

  • David J. Pinato
  • James R. M. Black
  • Ramya Ramaswami
  • Tricia M. Tan
  • Delali Adjogatse
  • Rohini SharmaEmail author
Short Communication


There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on its efficacy in treating mPGL are scarce. We report safety and efficacy outcomes from a case series of five patients with advanced mPGLs treated with 177Lu-DOTATATE PRRT. The mean age of our cohort was 34 years (range 16–47); 4 patients were male with bone disease being the most prevalent metastatic site. PRRT scheme varied between 1 and 4 cycles, with premature cessation due to suspected pneumonitis in one case and disease progression in another. Three patients with previously documented progressive disease achieved stabilization following treatment; one had partial response and one was treatment refractory. Median progression-free survival was 17 months (range 0–78 months). 177-Lu-DOTATATE is an effective therapy in mPGLs in this molecularly defined patient cohort, warranting further investigation in larger studies including hereditary and sporadic mPGL.


Malignant paraganglioma Management Peptide receptor radionuclide therapy Survival 


Compliance with ethical standards

Conflict of interest



  1. 1.
    Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14:569–85.CrossRefPubMedGoogle Scholar
  2. 2.
    Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52:334–40.PubMedGoogle Scholar
  3. 3.
    Gao B, Kong F, Xu Z. Development of differential diagnosis for benign and malignant pheochromocytomas. Int J Urol. 2008;15:771–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Gimm O, DeMicco C, Perren A, Giammarile F, Walz MK, Brunaud L. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg. 2012;397:155–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S103–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O’Dorisio TM, Valkema R, Bodei L, Chinol M, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):62S–6S.PubMedGoogle Scholar
  9. 9.
    Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Lowery AJ, Walsh S, McDermott EW, Prichard RS. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist. 2013;18:391–407.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep. 2004;6:477–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Petri BJ, van Eijck CH, de Herder WW, Wagner A, de Krijger RR. Phaeochromocytomas and sympathetic paragangliomas. Br J Surg. 2009;96:1381–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Pinato DJ, Ramachandran R, Toussi ST, Vergine M, Ngo N, Sharma R, Lloyd T, Meeran K, Palazzo F, Martin N, et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer. 2013;108:429–37.Google Scholar
  14. 14.
    Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K, Ngo N, Dina R, Sharma R. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer. 2014;110:115–22.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, Tyler DS, Olson JA Jr. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134:956–62 discussion 962–953.CrossRefPubMedGoogle Scholar
  16. 16.
    Schulte KM, Talat N, Galata G, Aylwin S, Izatt L, Eisenhofer G, Barthel A, Bornstein SR. Genetics and the clinical approach to paragangliomas. Horm Metab Res. 2014;46:964–73.CrossRefPubMedGoogle Scholar
  17. 17.
    van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, Wolbers JG, Kwekkeboom DJ. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599–606.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • David J. Pinato
    • 1
  • James R. M. Black
    • 1
  • Ramya Ramaswami
    • 2
  • Tricia M. Tan
    • 4
  • Delali Adjogatse
    • 2
  • Rohini Sharma
    • 1
    • 3
    Email author
  1. 1.Division of Surgery and Cancer, Imperial College LondonHammersmith HospitalLondonUK
  2. 2.Department of Medical Oncology, Imperial College LondonHammersmith HospitalLondonUK
  3. 3.Division of Oncology and Clinical Pharmacology, Imperial College LondonHammersmith CampusLondonUK
  4. 4.Division of Diabetes, Endocrinology and Metabolism, Department of Investigative MedicineImperial College LondonLondonUK

Personalised recommendations